Tenofovir Alafenamide Hemifumarate: A Comprehensive Guide
Discover the advanced benefits and applications of Tenofovir Alafenamide Hemifumarate in modern medicine.
Get a Quote & SampleProduct Core Value
Tenofovir Alafenamide Hemifumarate
Tenofovir Alafenamide Hemifumarate (TAF) is a cutting-edge nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It is highly effective in treating HIV-1 infection and chronic Hepatitis B virus (HBV) infection by significantly increasing intracellular tenofovir concentrations while lowering serum levels. This improved profile leads to reduced exposure for the kidneys and bones, making it a valuable advancement in antiviral therapy.
- Explore the key benefits of TAF hemifumarate drug mechanism in our detailed analysis.
- Understand why tenofovir alafenamide fumarate 1392275-56-7 is crucial for modern HIV treatment.
- Learn about the efficacy of Tenofovir Alafenamide Hemifumarate in Hepatitis B treatment.
- Discover the advantages of prodrug tenofovir alafenamide benefits for patient health.
Key Advantages
Enhanced Efficacy
TAF exhibits superior cellular delivery of tenofovir, resulting in higher intracellular active drug levels, which is a core component of its effectiveness in antiviral therapies. This aligns with research on prodrug tenofovir alafenamide benefits.
Improved Safety Profile
The lower serum levels associated with TAF contribute to a better safety profile, particularly concerning kidney and bone health, a significant improvement over older formulations and a key aspect of tenofovir alafenamide safety profile.
Targeted Delivery
As a prodrug, TAF is designed for targeted delivery, optimizing the concentration of the active metabolite where it is needed most, a critical factor in effective HIV treatment and Hepatitis B treatment.
Key Applications
HIV-1 Treatment
TAF plays a vital role in combination therapies for HIV-1, offering a more favorable safety profile, as supported by studies on tenofovir alafenamide fumarate 1392275-56-7.
Chronic Hepatitis B Treatment
It is also approved for treating chronic Hepatitis B virus (HBV) infection, contributing to viral suppression and management of the disease.
Pharmaceutical Intermediates
As an API, it serves as a critical component in the manufacturing of various pharmaceutical formulations aimed at combating viral infections.
Research and Development
TAF is a subject of ongoing research for its potential in new therapeutic strategies and understanding its detailed tenofovir alafenamide safety profile.